Vaxart Faces Significant Legal Setback in Court Ruling

A federal court has ruled in favor of former major shareholder Armistice Capital in a pivotal legal dispute, dealing a substantial blow to Vaxart’s attempt to reclaim $87 million in profits. The definitive judgment effectively blocks the biotechnology company from recovering these funds.

The case centered on short-swing transactions and warrant adjustments approved by Vaxart’s board related to Armistice Capital’s trading activities following a major corporate announcement in 2020.

Legal Decision Resolves Major Financial Uncertainty

At the heart of the matter was a shareholder attempt to force Armistice Capital to disgorge $87 million in profits under Section 16(b) of the Securities Exchange Act. The hedge fund had realized these gains after exercising warrants and subsequently closing its position in Vaxart.

These transactions occurred shortly after Vaxart’s June 2020 announcement that its oral COVID-19 vaccine candidate had been selected for a US government-sponsored study. The district court determined that Rule 16b-3(d) exempts Armistice from liability in this matter.

Judges based their decision on the finding that Vaxart’s board was aware that Armistice representatives on the board were acting on behalf of the short-swing trader when they approved the warrant adjustments.

Should investors sell immediately? Or is it worth buying Vaxart?

Company Navigates Multiple Challenges Amid Legal Setback

The legal clarification arrives during a turbulent period for the clinical-stage company:

• A US government “Stop Work Order” issued on August 5 has impeded screening and recruitment for the COVID-19 Phase 2b clinical trial
• While Q2 2025 financial results showed government-funded revenue of $39.7 million, the company still reported a net loss of $15.0 million
• The company’s shares declined 3.17% yesterday, closing at $0.36

The court’s decision carries significant financial implications, permanently eliminating the potential $87 million inflow to Vaxart’s balance sheet. While resolving longstanding uncertainty, the ruling simultaneously removes a substantial potential capital source for the company.

Financial Position and Strategic Initiatives

Without this potential funding, Vaxart’s financial standing relies on its current resources. As of June 30, 2025, the company holds $26.3 million in cash and investments, which management believes provides sufficient liquidity through the first quarter of 2026—assuming no additional partnerships or financing arrangements are secured.

Several critical milestones approach on Vaxart’s strategic calendar. Shareholders face a September 4 deadline to vote on a reverse stock split proposal, a move intended to maintain the company’s Nasdaq listing eligibility. A special meeting concerning this matter has been scheduled for September 5.

Despite current operational challenges, Topline data from the COVID-19 Phase 2b study isn’t anticipated until late 2026. More immediately, Phase 1 results for the company’s norovirus vaccine candidate could emerge by mid-2025. Concurrently, Vaxart continues pursuing strategic partnerships and non-dilutive financing alternatives to strengthen its financial position.